Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the closing of a $210 million private financing to advance its next wave of tech-enabled small molecule medicines. The round was co-led by new investor GV (Google Ventures) and existing investors SR One and Atlas Venture, with participation from another new investor that is a U.S.-based life sciences-focused fund as well as existing investors Bain Capital Life Sciences, BVF Partners L.P., Gates Frontier, Lightstone Ventures, Pfizer Ventures, RA Capital Management, and SV Health Investors..

Nimbus Therapeutics是一家临床阶段公司，通过其强大的计算药物发现引擎设计和开发突破性药物，宣布关闭2.1亿美元的私人融资，以推进下一波技术支持的小分子药物。这一轮由新投资者GV（Google Ventures）和现有投资者SR One和Atlas Venture共同领导，另一位新投资者是美国生命科学重点基金，以及现有投资者Bain Capital life sciences，BVF Partners L.P.，Gates Frontier，Lightstone Ventures，Pfizer Ventures，RA Capital Management和SV Health投资者参与。。